DiaMedica-Aktien behalten “Kaufen”-Rating by HC Wainwright from Investing.com

DiaMedica Therapeutics Inc. (NASDAQ: DMAC) has been given a “Kaufen” rating by HC Wainwright with a price of US$7.00.

This Empfehlung has started while the third phase of a phase 2 study for the lead candidates DM199 by treating the Präeklampsia (PE) was being conducted. Präeklampsie is een schwerwiegende Schwangerschaftskomplikation, die wie Bluthochdruck gekennzeichnet.

The further study, which will start in four years in the quarter of 2024, will be carried out at the Tygerberg Hospital in Kapstadt, South Africa. DiaMedica has established the Hereditary Generation of the South African Health Care Association (SAHPRA), after the Ethics Committee for Health Research at Stellenbosch University in June 2024, because the Zustimmung erteilt hatte. The first years of the first part of the study were carried out before the first half of the year 2025.

DM199, which can be considered as rinvecalinase alfa, is a recombinant form of human gewebekallikrein-1 (rhKLK1). If you act with a serin protease enzyme, the action of the fluid and pee aperfusion in patients with extensive treatment is carried out. These are safe during very high production of prostacyclin, prostacyclin and endothelial hyperpolarizing factors (EDHFs). The active effect of Bradykinin-2 (BK2) receptors on endothelial cells will contribute to the improvement of the effects caused by präeklampsie.

The clinical fortress of DM199 no longer applies, but it is a standard extinguisher for shy women with preeklampsie money. Treat the treatment with ACE-hemmer or Angiotensin-Rezeptor-Blocker (ARBs) without the Schwangerschaft is not good. This uncovered medical treatment gives DM199 a chance, your therapeutic effect is demonstrated.

In others, DiaMedica Therapeutics is active in clinical research and financing the situation. As part of South Africa’s healthcare development, a phase 2 trial of DM199 is underway, while the proprietary recombinant serin protease for treatment of the bulb begins.

That study is being conducted at Tygerberg Hospital in Kapstadt, South Africa, under the direction of Prof. Catherine Cluver, MD, PhD, durchgeführt. DiaMedica right with the beginning of the dose in the quarter 2024.

HC Wainwright has conducted the treatment of DiaMedica Therapeutics with a “Kaufen” rating based on the potential of DM199, that there has been an uncovered decay and a Schlaganfall treatment on the deck. Darüber reported DiaMedica on June 30, 2024 a healthy financial situation with 54.1 million US dollars and investments and investments. If you make a trade in the Vergleich, it is a matter of all the costs and expenses that a business entails, a higher level of sentences on market paper is generated.

DiaMedica Therapeutics has development power with ReMEDy2, a study examining DM199 for its potential in the treatment of ischemic diseases and dissecting research. Full-fledged recruitment for the study has commenced until the first quarter of 2025.

InvestingPro Insights

Während DiaMedica Therapeutics Inc. (NASDAQ:DMAC) has tendered multiple DM199 funding consideration candidates, but has financial backing from InvestingPro and the associated context for investors. The market capitalization of the internal market was US$192.37 million, and the active market claim was potentially more broadly mirrored.

InvestingPro-Tipps ensured that DiaMedica had more Barmittel as debt in the Bilanz project, was the financial flexibility for the Eintritt in the separate Phase 2 Study studies that were possible. This strong cash position is driven by the high quality of the economy, while clinical trials funding is a critical factor for the development-stage biotech industry.

The positive clinical results are likely that analysts used another article from InvestingPro-Tipp, but this could be a profitable venture. There is nothing new for the biotech companies, the strong investments in Forschung and Entwicklung. The fact that the campaign had delivered a strong 50% performance in the last three months may have been the anleger’s optimism that the study reflected more broadly.

For those years you can analyze some of the interests, with InvestingPro 7 other tips, which make even more money in the financial sector and the market forces of DiaMedica.

This description can be performed by the intelligent intelligence. Weitere Informationen entnehmen Sie bitte unseren Nutzungsbedingungen.